Health Care
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Gopher State's Suit Galls UnitedHealth
- Biolase: Letter Perfect?
- National Health Terms Buyout Bid Inadequate
- Del.icio.us
- Digg
- StumbleUpon
Abiomed(ABMD - Cramer's Take - Stockpickr) late Thursday issued downside revenue guidance for its second quarter ended Sept. 30. The maker of heart-pumping devices forecast sales of $11 million, below Street consensus of $13.3 million in revenue, but a tad higher than reported revenue in the same period last year of $10.9 million. "Our strategic platforms of Impella and AB5000 (consoles and disposables) performed well during the quarter," said CEO Michael Minogue, who added that revenue for BVS (blood pumps) declined. After hours, shares of the Danvers, Mass.-based company slipped 6.7%, or 95 cents, to $14.05. The company will give full second-quarter 2007 results on Nov. 8. Abiomed closed the regular session up 2 cents to $15.
10/12/06
Gopher State's Suit Galls UnitedHealth
Prosecutors in Minnesota expand an option-backdating case.
10/12/06
Biolase: Letter Perfect?
An FDA warning suggests case may not be closed.
10/10/06
National Health Terms Buyout Bid Inadequate
The company's CEO has offered $30 a share.
08/05/08
Three Internet Stocks That Could Double
These forgotten Internet stocks are being accumulated by hedge funds.
08/15/08
The Five Dumbest Things on Wall Street
Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...
08/15/08
McCain Fund-Raising Picks Up
The GOP presidential candidate raised $27 million in July.
08/15/08
Cash-Back Cards Aren't Money in the Bank
Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.
More popular tickers are indicated by scale.
Sponsored by:
RSS
